TY - JOUR
T1 - Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis
AU - Liang, Jinping
AU - Teng, Xindong
AU - Yuan, Xuefeng
AU - Zhang, Ying
AU - Shi, Chunwei
AU - Yue, Tingting
AU - Zhou, Lei
AU - Li, Jianrong
AU - Fan, Xionglin
N1 - Funding Information:
This work was supported by grants from the National High Technology Research and Development of China (863 program No. 2012AA02A401 ) and the National Mega-projects of Science Research for the 12th Five-year Program of China (No. 2012ZX10003008-005 ).
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015
Y1 - 2015
N2 - Although Bacillus Calmette-Guérin (BCG) vaccine confers protection from Mycobacterium tuberculosis infection in children, its immune protection gradually wanes over time, and consequently leads to an inability to prevent the reactivation of latent infection of M. tuberculosis. Therefore, improving BCG for better control of tuberculosis (TB) is urgently needed. We thus hypothesized that recombinant BCG overexpressing immunodominant antigens expressed at different growth stages of M. tuberculosis could provide a more comprehensive protection against primary and latent M. tuberculosis infection. Here, a novel cocktail of recombinant BCG (rBCG) strains, namely ABX, was produced by combining rBCG::85A, rBCG::85B, and rBCG::X, which overexpressed respective multistage antigens Ag85A, Ag85B, and HspX of M. tuberculosis. Our results showed that ABX was able to induce a stronger immune protection than individual rBCGs or BCG against primary TB infection in C57BL/6 mice. Mechanistically, the immune protection was attributed to stronger antigen-specific CD4+ Th1 responses, higher numbers of IFN-γ+ CD4+ TEM and IL-2+ CD8+ TCM cells elicited by ABX. These findings thus provide a novel strategy for the improvement of BCG efficacy and potentially a promising prophylactic TB vaccine candidate, warranting further investigation.
AB - Although Bacillus Calmette-Guérin (BCG) vaccine confers protection from Mycobacterium tuberculosis infection in children, its immune protection gradually wanes over time, and consequently leads to an inability to prevent the reactivation of latent infection of M. tuberculosis. Therefore, improving BCG for better control of tuberculosis (TB) is urgently needed. We thus hypothesized that recombinant BCG overexpressing immunodominant antigens expressed at different growth stages of M. tuberculosis could provide a more comprehensive protection against primary and latent M. tuberculosis infection. Here, a novel cocktail of recombinant BCG (rBCG) strains, namely ABX, was produced by combining rBCG::85A, rBCG::85B, and rBCG::X, which overexpressed respective multistage antigens Ag85A, Ag85B, and HspX of M. tuberculosis. Our results showed that ABX was able to induce a stronger immune protection than individual rBCGs or BCG against primary TB infection in C57BL/6 mice. Mechanistically, the immune protection was attributed to stronger antigen-specific CD4+ Th1 responses, higher numbers of IFN-γ+ CD4+ TEM and IL-2+ CD8+ TCM cells elicited by ABX. These findings thus provide a novel strategy for the improvement of BCG efficacy and potentially a promising prophylactic TB vaccine candidate, warranting further investigation.
KW - Ag85 complex
KW - HspX
KW - Mycobacterium tuberculosis
KW - Recombinant BCG
KW - Tuberculosis
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84938829620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938829620&partnerID=8YFLogxK
U2 - 10.1016/j.molimm.2015.04.017
DO - 10.1016/j.molimm.2015.04.017
M3 - Article
C2 - 25974877
AN - SCOPUS:84938829620
SN - 0161-5890
VL - 66
SP - 392
EP - 401
JO - Molecular Immunology
JF - Molecular Immunology
IS - 2
ER -